Advanced MRD testing in multiple myeloma, CLL, B-ALL, and DLBCL

Pinpoint where your blood cancer stands with clonoSEQ®

What is clonoSEQ?

clonoSEQ (pronounced clo-no-seek) measures minimal residual disease (MRD). This helps uncover how much, if any, cancer remains in your body during and after treatment.1

Knowing your MRD status can help you and your doctor manage decisions along your cancer journey.


MRD status icon

MRD is one of the strongest predictors of outcomes in blood cancers


Graph showing changes in disease over time

Using clonoSEQ, your doctor can monitor your cancer by assessing treatment response and detecting changes in disease


This comprehensive program supports patients throughout their clonoSEQ MRD testing


If you have multiple myeloma, CLL, B-ALL, or DLBCL, talk with your doctor about tracking your MRD status with clonoSEQ.

Questions to ask your doctor

References to “blood cancer” on this webpage refer specifically to multiple myeloma, CLL, B-ALL, and DLBCL.

This page is intended for a US-based audience.

clonoSEQ® is an FDA-cleared test used to detect minimal residual disease (MRD) in bone marrow from patients with multiple myeloma or B-cell acute lymphoblastic leukemia (B-ALL) and blood or bone marrow from patients with chronic lymphocytic leukemia (CLL). clonoSEQ is also available for use in other lymphoid cancers and specimen types as a CLIA-validated laboratory developed test (LDT).

clonoSEQ is only available by prescription from a licensed healthcare professional. Results may vary. Talk to your healthcare provider to see if clonoSEQ testing is right for you. For important information about the FDA-cleared uses of clonoSEQ including test limitations, please visit clonoSEQ.com/technical-summary.